Saturday 17 October 2026
Export HELP’s income statement to Excel — free account
Cybin Inc.
HELP Healthcare Biotechnology
In the quarter to June 2026, EPS grew 17.3% and free cash flow fell 25.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
10.55
0.50
−4.52%
Follow HELP
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(53.50%) | (54.91%) | (74.60%) | (86.94%) | |
| (46.67%) | (51.91%) | (68.67%) | (72.78%) | ||
ROIC |
(73.61%) | (93.51%) | (119.57%) | (137.88%) | |
Return on Tangible Assets |
(86.02%) | (59.11%) | (89.51%) | (97.66%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(4.09) | (2.65) | (3.87) | (2.72) | |
Free Cash Flow |
(98.99) | (112.51) | (134.63) | (142.25) | |
Capital Expenditures |
(1.63) | (1.79) | (1.36) | (1.46) | |
| Other line items | |||||
Cash ROIC |
(39.34%) | (23.99%) | (34.61%) | (34.83%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
1.12 | 0.91 | 0.90 | 0.82 | |
Depreciation/Fixed assets |
1.67 | 0.74 | 0.62 | 0.63 | |
Capex/Depreciation |
(7.79) | (13.10) | (11.36) | (12.94) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(4.02) | (2.60) | (3.83) | (2.69) | |
Capex per Share |
(0.07) | (0.04) | (0.04) | (0.03) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates